AI-Powered Platform Targets Autism and ADHD
BlinkLab Limited, an Australian digital healthcare company listed on ASX as BB1, has secured AUD 17.5 million in an oversubscribed placement. This funding round aimed at institutional and sophisticated investors was priced at AUD 0.65 per share. It enables BlinkLab to expedite FDA trials and commercial launch of its AI-powered autism diagnostic tool, BlinkLab Dx1, while expanding into the ADHD market with its BlinkLab Dx2 platform. These efforts are part of BlinkLab’s strategy to target the large, underserved global market for neurodevelopmental diagnostics.
This capital raise supports BlinkLab’s late-stage regulatory readiness for BlinkLab Dx1. Strong pilot data have already exceeded FDA-agreed performance thresholds. Now, the company is focused on generating real-world evidence and building commercial infrastructure in the United States. The funds will also assist in completing the pivotal FDA 510(k) registrational trial for autism, progressing CE marking, and gaining EU MDR approval.
The company’s AI-driven, smartphone-based platform is designed to deliver scalable, objective diagnostic support. This aligns with the rising regulatory and clinical adoption of digital biomarkers and artificial intelligence in healthcare. BlinkLab is preparing to initiate U.S. clinical studies for its ADHD diagnostic tool, BlinkLab Dx2, targeting a significantly larger patient demographic. This expansion leverages existing infrastructure, allowing cost-effective growth and strengthening BlinkLab’s positioning as a multi-indication digital diagnostics platform.
BlinkLab’s CEO, Dr Henk-Jan Boele, emphasised the team’s dedication by stating, “This capital raise is another major milestone for BlinkLab. It is a direct result of the incredible dedication shown by our team and our clinical partners.” Chairman Brian Leedman highlighted investor support, noting, “We are very pleased with the strong support received for this placement, particularly from high-quality institutional investors who share our long-term vision.”
The funding marks a critical phase in BlinkLab’s growth, addressing significant unmet needs in neurodevelopmental diagnostics. BlinkLab aims to complete the U.S. study for ADHD and progress towards FDA approval while enhancing its European regulatory strategy. As the company expands its clinical pipeline, it is poised to significantly impact the diagnostics industry.
Last updated: 17 April 2026, 3:19 am
